MediciNova, Inc.

MNOV Healthcare Biotechnology

MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.

1.42 0.03 −2.07%
Market cap
$71.4M
P/E
0.0×
Fwd P/E
−5.0×
Dividend yield
—
F-score
n/a
Altman Z
−4.10
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
48.08 45.60 113.03 70.59
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(36.57) (31.87) (19.43) (33.84)
P/B ratio
1.42 1.55 1.71 1.74
Price to Tangible BV
1.81 2.01 2.26 2.35
EV/Sales
22.95 23.74 67.22 42.98
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(3.06) (3.41) (4.22) (4.34)
EV/FCF
(3.06) (3.41) (4.22) (4.34)
Quick Ratio
9.76 8.11 8.91 8.58
Current Ratio
9.86 8.16 9.09 8.75
Net Debt/EBITDA
9.65 9.98 9.65 10.02
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.02 0.03 0.01 0.02
Operating CF/Net income
0.56 0.72 1.34 0.83
Capex/Depreciation
(0.55) 0.00 (2.51) 0.00
Research and Development Expense of Revenue
1,283.86% 1,017.40% 675.13% 224.52%
Selling, General and Administrative Expense of Revenue
1,464.80% 1,024.19% 850.37% 399.17%
Intangible Assets out of Total Assets
0.20 0.21 0.22 0.24
Share Based Compensation of Revenue
127.90% 119.05% 218.07% 38.55%
Graham Net Nets
0.47 0.42 0.37 0.35
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(19.69%) (18.32%) (16.79%) (15.91%)
Free Cash Flow Yield
(15.62%) (15.27%) (14.10%) (14.04%)
Revenue per Share
0.00 0.00 0.00 0.01
Operating CF per Share
(0.03) (0.04) (0.07) (0.04)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.03) (0.04) (0.07) (0.04)
Cash per Share
0.66 0.63 0.56 0.52
Shareholders Equity per Share
0.90 0.85 0.80 0.76
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.90 0.85 0.80 0.76
Free Cash Flow
(1.71) (2.02) (3.48) (1.92)
Working Capital
29.59 27.19 25.05 22.96
Capital Expenditures
0.00 0.00 (0.01) 0.00
Net Current Asset Value
29.31 26.97 24.85 22.76
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.00 0.06 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Payables
0.73 0.86 0.79 0.76
Average Assets
52.85 50.74 47.57 45.13
Average Common Equity
49.52 47.05 44.67 42.06

Fold the line items

Columns are period end dates